CN103068812A - 沙利度胺晶型及其制备方法 - Google Patents

沙利度胺晶型及其制备方法 Download PDF

Info

Publication number
CN103068812A
CN103068812A CN2011800385583A CN201180038558A CN103068812A CN 103068812 A CN103068812 A CN 103068812A CN 2011800385583 A CN2011800385583 A CN 2011800385583A CN 201180038558 A CN201180038558 A CN 201180038558A CN 103068812 A CN103068812 A CN 103068812A
Authority
CN
China
Prior art keywords
crystalline
thalidomide
equal
anhydrous
purity greater
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN2011800385583A
Other languages
English (en)
Chinese (zh)
Inventor
维纳亚克·戈文德·戈雷
维纳伊·库玛·舒克拉
马杜卡尔·帕蒂尔
桑迪普·梅克德
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Generics UK Ltd
Original Assignee
Generics UK Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Generics UK Ltd filed Critical Generics UK Ltd
Publication of CN103068812A publication Critical patent/CN103068812A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN2011800385583A 2010-06-09 2011-06-09 沙利度胺晶型及其制备方法 Pending CN103068812A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN1758MU2010 2010-06-09
IN1758/MUM/2010 2010-06-09
PCT/GB2011/051078 WO2011154739A1 (en) 2010-06-09 2011-06-09 Crystalline forms of thalidomide and processes for their preparation

Publications (1)

Publication Number Publication Date
CN103068812A true CN103068812A (zh) 2013-04-24

Family

ID=44384914

Family Applications (1)

Application Number Title Priority Date Filing Date
CN2011800385583A Pending CN103068812A (zh) 2010-06-09 2011-06-09 沙利度胺晶型及其制备方法

Country Status (8)

Country Link
US (2) US20130143923A1 (enExample)
EP (1) EP2580205A1 (enExample)
JP (1) JP2013528206A (enExample)
CN (1) CN103068812A (enExample)
AU (1) AU2011263493B2 (enExample)
CA (1) CA2801835A1 (enExample)
NZ (1) NZ604011A (enExample)
WO (1) WO2011154739A1 (enExample)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104710411A (zh) * 2015-03-13 2015-06-17 安润医药科技（苏州）有限公司 阿伐那非的合成方法
CN105473558A (zh) * 2013-06-20 2016-04-06 拜耳作物科学股份公司 作为杀螨剂和杀昆虫剂的芳基硫化物衍生物和芳基硫氧化物衍生物
CN110498788A (zh) * 2018-05-16 2019-11-26 欣凯医药化工中间体（上海）有限公司 一种高纯度沙利度胺α晶型的制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102924432A (zh) * 2012-11-09 2013-02-13 常州制药厂有限公司 一种高纯度沙利度胺的制备方法
EP2815749A1 (en) * 2013-06-20 2014-12-24 IP Gesellschaft für Management mbH Solid form of 4-amino-2-(2,6-dioxopiperidine-3-yl)isoindoline-1,3-dione having specified X-ray diffraction pattern
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
MX387318B (es) * 2014-04-14 2025-03-18 Arvinas Operations Inc Moduladores de la proteólisis basados en imida y métodos de uso asociados.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1405166A (zh) * 2002-10-28 2003-03-26 中国科学院长春应用化学研究所 沙利度胺及其衍生物的制备方法
WO2008035378A2 (en) * 2006-09-20 2008-03-27 Matrix Laboratories Ltd An improved process for the preparation of thalidomide
CN102260241A (zh) * 2010-05-26 2011-11-30 重庆医药工业研究院有限责任公司 一种沙利度胺α晶型的工业化制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB768821A (en) 1954-05-17 1957-02-20 Gruenenthal Chemie Novel products of the amino-piperidine-2, 6-dione series
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
US20050182097A1 (en) * 2003-12-30 2005-08-18 Zeldis Jerome B. Methods and compositions using thalidomide for the treatment and management of central nervous system disorders or diseases
ITMI20041113A1 (it) 2004-06-01 2004-09-01 Antibioticos Spa Processo per la sintesi della talidomide
WO2009083724A1 (en) 2007-12-27 2009-07-09 Cipla Limited Processes for the preparation of thalidomide

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1405166A (zh) * 2002-10-28 2003-03-26 中国科学院长春应用化学研究所 沙利度胺及其衍生物的制备方法
WO2008035378A2 (en) * 2006-09-20 2008-03-27 Matrix Laboratories Ltd An improved process for the preparation of thalidomide
CN102260241A (zh) * 2010-05-26 2011-11-30 重庆医药工业研究院有限责任公司 一种沙利度胺α晶型的工业化制备方法

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
陈芊茜等: ""沙利度胺晶型药物的表征与晶型稳定研究"", 《第二届中国晶型药物研发技术研讨会会议交流论文》 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105473558A (zh) * 2013-06-20 2016-04-06 拜耳作物科学股份公司 作为杀螨剂和杀昆虫剂的芳基硫化物衍生物和芳基硫氧化物衍生物
CN105473558B (zh) * 2013-06-20 2019-04-19 拜耳作物科学股份公司 作为杀螨剂和杀昆虫剂的芳基硫化物衍生物和芳基硫氧化物衍生物
CN104710411A (zh) * 2015-03-13 2015-06-17 安润医药科技（苏州）有限公司 阿伐那非的合成方法
CN104710411B (zh) * 2015-03-13 2017-04-26 安润医药科技（苏州）有限公司 阿伐那非的合成方法
CN110498788A (zh) * 2018-05-16 2019-11-26 欣凯医药化工中间体（上海）有限公司 一种高纯度沙利度胺α晶型的制备方法
CN110498788B (zh) * 2018-05-16 2021-09-17 欣凯医药化工中间体（上海）有限公司 一种高纯度沙利度胺α晶型的制备方法

Also Published As

Publication number Publication date
US20150218126A1 (en) 2015-08-06
US20130143923A1 (en) 2013-06-06
NZ604011A (en) 2015-04-24
AU2011263493A1 (en) 2013-01-10
AU2011263493B2 (en) 2015-08-06
JP2013528206A (ja) 2013-07-08
CA2801835A1 (en) 2012-12-15
EP2580205A1 (en) 2013-04-17
AU2011263493A8 (en) 2013-02-21
WO2011154739A1 (en) 2011-12-15

Similar Documents

Publication Publication Date Title
US20150218126A1 (en) Crystalline forms of thalidomide and processes for their preparation
KR101019451B1 (ko) 이마티닙 메실레이트의 다형 및 신규한 결정형과 비결정형및 α형의 제조 방법
CN102272118A (zh) 来那度胺的晶型及其制备方法
US7977348B2 (en) Polymorphic forms of imatinib mesylate and processes for preparation of novel crystalline forms as well as amorphous and form α
CN101939303B (zh) 波生坦的晶型
KR20040077872A (ko) 카베디롤의 결정질 고체 및 그 제조 방법
JP2009514988A (ja) イマチニブ塩基及びイマチニブメシレート、及びそれらの調製方法
WO2012044595A1 (en) Dabigatran etexilate bismesylate salt, solid state forms and process for preparation thereof
CN101772491A (zh) 基本不含有二聚体杂质的瑞格列奈
JP2000063363A (ja) 新規なトリアゾール誘導体
WO2014194795A1 (zh) 吲哚酮化合物或其衍生物及其用途
US20090018182A1 (en) Crystalline forms of atorvastatin
JP2012509930A (ja) 新規な方法および純粋な多型
JP2016504364A (ja) コビシスタット塩
KR20130055576A (ko) 고순도의 결정질 이마티닙 염기를 제조하는 방법
JP2009543773A (ja) ＨＭＧ−ＣｏＡレダクターゼ阻害剤の多形体及びその使用
CN101160281A (zh) 结晶形态的普瑞巴林
WO2020173417A1 (zh) 含丙烯酰基的核转运调节剂及其用途
KR20070072588A (ko) 텔미사르탄 나트륨의 비정질형 및 다형
WO2015037010A1 (en) Preparation of vilazodone hydrochloride crystalline form iv
JP2024505736A (ja) ３－ヒドロキシ－５－プレグナン－２０－オン誘導体の結晶形およびその製造方法と使用
WO2014012480A1 (zh) 氘代ω-二苯基脲或其盐的多晶型物
WO2019175722A1 (en) Process for the preparation of stable and highly pure crystalline form 2 of bilastine
WO2020156150A1 (zh) 泊马度胺前体药物盐的多晶型物
WO2023222946A1 (en) Process for the preparation of cabozantinib

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20130424

RJ01 Rejection of invention patent application after publication